MBBS - Gandhi Medical College , University Of Health Sciences - 1996 - Hyderabad Verified
Certification - ECFMG - 1997 Verified
Certification - Internal Medicine - Barnabas Medical Center Livingston - 2001 - NJ , USA Verified
Certification Course - Medical Oncology - American Board - 2014 - USA Verified
Certification Course - Hematology - American Board - 2014 - USA Verified
Fellowship In Hematology And Oncology - Caritas St. Elizabeth’s Medical Center Tufts University School Of Medicine Boston, - 2005 - MA. USA Verified
Experiences
Assistant Professor - Head Of Department Of Medical Oncology MNJ Institute Of Oncology And Regional Cancer Center , Hyderabad - 2007 - 2017
Senior Consultant In Hematology And Oncology Continental Hospitals , Hyderabad - 2014 - 2017
Consultant Medical Oncologist American Oncology Institute , Hyderabad
Consultant Medical Oncologist Fernandez Hospital - Hyderguda - Currently Working
Consultant Medical Oncologist MNJ Institute of Oncology & Regional Cancer Centre - Lakdi Ka Pul - Currently Working
Registrations
40091 Andhra Pradesh Medical Council 1997 Verified
Paper Presentations
Research and Articles :
Expression and purification of Erythrocyte Macrophage Protein (EMP)
Development of anti-EMP antibodies
Design and development of FP1 (Cystein Protease enzyme Falpain 1) knock out constructs – This is an enzyme that is likely involved in the release of malarial merozoites from host RBCs.
Publications :
Digumarti R- Sinha S- Nirni SS- Patil SG- Pedapenki RM. Indian J Cancer. 2014 Apr-Jun;51(2):180-3. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
Cingeetham A- Vuree S- Dunna NR- Gorre M- Nanchari SR- Edathara PM- Meka P- Annamaneni S- Digumarthi R- Sinha S- Satti V. Tumour Biol. 2015 May 10. [Epub ahead of print]. Influence of BCL2-938C >A and BAX-248G>A promoter polymorphisms in the development of AML: case-control study from South India
Cingeetham A1- Vuree S- Jiwatani S- Kagita S- Dunna NR- Meka PB- Gorre M- Annamaneni S- Digumarti R- Sinha S- Satti V. Asian Pac J Cancer Prev. 2015;16(7):2707-12. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development
Cingeetham A- Vuree S- Dunna NR- Gorre M- Nanchari SR- Edathara PM- Mekkaw P- Annamaneni S- Digumarthi RR- Sinha S- Satti V.Tumour Biol. 2014 Sep;35(9):8813-22. Association of caspase9 promoter polymorphisms with the susceptibility of AML in south Indian subjects.
Chiranjeevi P- Spurthi KM- Rani NS- Kumar GR- Aiyengar TM- Saraswati M- Srilatha G- Kumar GK- Sinha S- Kumari CS- Reddy BN- Vishnupriya S- Rani HS. Tumour Biol. 2013 Dec 20. [Epub ahead of print]. Gelatinase B (-1562C/T) polymorphism in tumor progression and invasion of breast cancer.
Anuradha V- Anand BB- Suresh AV- Sinha S- Babu SC- Suresh K.Indian J Med Paediatr Oncol. 2013 Jan;34(1):11-5. Palliative chemotherapy in head and neck squamous cell cancer – What is best in Indian population? A time without symptoms- treatment toxicity score based study.
Attili SV- Ananda B- Mandapal T- Anjaneyulu V- Sinha S